Compare Incyte Corporation (INCY) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Global X SuperDividend ETF — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Global X SuperDividend ETF trades at $24.87. The key difference: Incyte Corporation is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| INCY | SDIV | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $118.52 | $26.34 |
52-Week Low | $67.38 | $22.90 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
SDIV trades at $24.73, down 0.72% on the day, with a neutral technical signal and bearish moving averages. The ETF maintains a high yield strategy, evidenced by recent $0.18 dividends. Support is firm at $24, while resistance clusters around $25. News sentiment is mixed, highlighting its appeal for income but noting valuation concerns compared to growth-focused strategies.
Outlook hinges on income-seeking demand amid stable global small-cap value exposure. The primary opportunity is its 9%+ yield for diversification away from tech. Risks include sensitivity to interest rates and economic cycles affecting high-dividend stocks, with limited fundamental data increasing reliance on technical and sentiment factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
